Keshavarz Khosro, Bordbar Mohammadreza, Hashemipoor Zeinab, Jalali Farideh Sadat, Ravangard Ramin
Health Human Resources Research Centre, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hematology. 2020 Dec;25(1):149-155. doi: 10.1080/16078454.2020.1741205.
To estimate the economic burden of hemophilia A and B in the patients referred to the related referral hospital in the south of Iran in 2017. This cross-sectional study was a partial economic evaluation and a cost of illness study, carried out in 2017. All the patients with hemophilia A and B referred to the related hospital affiliated to Shiraz University of Medical Sciences in the south of Iran were included in the study ( = = 253). A data collection form was used to collect the required data, including patients' direct and indirect costs. The mean annual cost was 36028 USD. The mean costs per patient with hemophilia A and B were 37661 USD and 30775 USD, respectively, in which the greatest part were related to direct medical costs (98.32% in hemophilia A, 98.18% in hemophilia B, and 98.29% of the total costs), and the cost of clotting factor concentrates accounted for the largest share of the patients' direct medical costs. Also, considering the number of hemophilia patients in Iran, the mean annual cost of the patients in 2017 was 414480325 USD, of which 381503701 USD was for hemophilia A and 32976624 USD was for hemophilia B patients. Considering the significant economic burden of hemophilia and in order to reduce the costs, the following suggestions can be offered: provision of clotting factor concentrates domestically in accordance with the world standards, and providing specialized services and care to hemophilia patients in towns.
评估2017年转诊至伊朗南部相关转诊医院的甲型和乙型血友病患者的经济负担。这项横断面研究是一项局部经济评估和疾病成本研究，于2017年开展。纳入了所有转诊至伊朗南部设拉子医科大学附属相关医院的甲型和乙型血友病患者（n = 253）。使用数据收集表收集所需数据，包括患者的直接和间接成本。年平均成本为36028美元。甲型和乙型血友病患者的人均成本分别为37661美元和30775美元，其中最大部分与直接医疗成本相关（甲型血友病中占98.32%，乙型血友病中占98.18%，总成本中占98.29%），凝血因子浓缩剂的成本在患者直接医疗成本中占比最大。此外，考虑到伊朗血友病患者的数量，2017年患者的年平均成本为414480325美元，其中甲型血友病患者为381503701美元，乙型血友病患者为32976624美元。鉴于血友病的巨大经济负担，为降低成本，可提出以下建议：按照国际标准在国内生产凝血因子浓缩剂，并在城镇为血友病患者提供专业服务和护理。
